The demand for Plasma Fractionation is witnessing an uptick on account of Geriatric Population and Plasma Collection Centers. The Plasma Fractionation market is expected to grow with a significant CAGR in the coming years. Plasma fractionation is the downstream processing of plasma that has been harvested by donors. It breaks plasma into individual proteins, or plasma fractions. This is different from whole blood fractionation, which means taking whole blood and breaking it into its four main parts. Over time, the scope of plasma fraction use has expanded and there are now over 20 different proteins that are of interest to the healthcare industry and therapeutics/biologics. In 2018, the number of plasma fractionation plants in the Asia-Pacific region stood at 39 while there were 21 plants in Europe.
Immunoglobulins are used as first-line therapy for various neurologic, immunologic, and hematologic conditions. The most common use of immunoglobulin therapy is for the treatment of primary immune deficiencies and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is also being considered for a range of neurological diseases, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome. In the last decade, the diagnosis rate of various immunological diseases has increased due to technological advancements. In addition, growing genetic research for characterizing and diagnosing immunodeficiency will increase the clinical need for immunoglobulins due to the increased number of diagnosed patients. Hemophilia or hematology disorders form one of the major application areas of plasma fractionation products. Hemophilia is a hereditary bleeding disorder characterized by impaired blood coagulation due to deficiencies in the production or function of coagulation factor VIII. According to the World Federation of Hemophilia, the number of hemophilia patients worldwide was 167,110 in 2011, which increased by 25.9% to 210,454 in 2018. Only 30% of patients are actually diagnosed with hemophilia, and 25% of them receive treatment. The rest of the people with hemophilia remain undiagnosed, and nearly 75% of patients receive inadequate treatment or no treatment at all.
The pandemic of coronavirus disease 2019 (COVID-19) has caused over millions of confirmed cases and hundreds of thousands of deaths worldwide as reported by the World Health Organization (WHO) and has shown tremendous impacts on globe health and economics. The Plasma Fractionation Market was also impacted during the pandemic because of involuntary medical services were stopped at the time. However, the Plasma Fractionation Market is expected to bounce back after the end of the pandemic.
Request For Sample: https://univdatos.com/get-a-free-sample-form-php/?product_id=18131
According to ‘UnivDatos Market Insights (UMI)’ research report “Plasma Fractionation Market Analysis, 2020”, the Plasma Fractionation market is projected to grow at a CAGR of ~6% during 2021-27. Increasing chronic diseases and plasma collection centers is one of the prominent reasons which is driving the market of the Plasma Fractionation. For Instance: In 2018, the global volume of source plasma stood at 55 million liters whereas recovered plasma stood at 6.5 million liters.
Based on the Product, the market is fragmented into Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, and Others. Immunoglobulins segment accounted for the largest share in 2020 and is anticipated to register a lucrative CAGR during the forecast period. Plasma-derived immunoglobulins are giving a new narrative to healthcare across a wide range of autoimmune inflammatory diseases. Clinically relevant antibody specific immunoglobulins include anti-D (anti-Rho), and antiHAV, anti-HBs, anti-tetanus, anti-varicella/herpes zoster and anti-rabies immunoglobulins.
Neurology Segment to Witness Robust growth
Based on Application, the market is fragmented into Neurology, Immunology, Hematology, Critical care, Pulmonology, and Others. Neurology Segment had the highest revenue and CAGR growth in the analyzed period. The largest share of this segment is mainly attributed to the surging neurological disorders that require plasma fractionation products and increasing research studies on plasma-derived products for neurological diseases. Additionally, the response of IVIg in a shorter period than steroids or oral immunosuppressants and its effectiveness in a number of disorders of the peripheral and central nervous systems is also a driving factor.
Request For Customization: https://univdatos.com/get-a-free-sample-form-php/?product_id=18131
Based on the End-User, the market is fragmented into Hospitals & Clinics, Clinical Research Laboratories, and others. Hospitals & Clinics segment accounted for the largest share in 2020 and is anticipated to register a lucrative CAGR during the forecast period. The growing need for therapies for immunodeficiency disorders, growing number of hospitals & healthcare expenditure, and rising consumption of plasma-derived products by hospitals & clinics are some of the major factors driving the growth of this segment.
North America to Grab Lion’s Share, and witnessed Explicit Growth
Based on the Region, North America dominated the Plasma Fractionation market in 2020. The region is projected to maintain its dominance during the forecasted period 2021-27 owing to increasing chronic diseases. For example, According to Centers of Disease Control (CDC) statistic, in 2012 chronic diseases were one of the major causes of death and disability in the U.S., with an estimated 117 million people suffering from some form of chronic disease. North America is expected to skyrocket with a CAGR of XX% in the forecast period owing, as stated in UnivDatos Market Insights (UMI)’ research report “Plasma Fractionation Market Analysis, 2020”.
According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the Baxter International Inc., Bio product laboratory, Biotest AG, CSL Ltd., Grifols SA, Kedrion S.P.A (Kedrion Biopharma Inc.), LFB S. A., Octapharma AG, Sanquin Blood Supply Foundation, and Takeda Pharmaceutical Company Limited among others. The players are focused on launching new products for gaining customers' traction and expanding their geographical reach to get a competitive edge in the industry.
“Plasma Fractionation Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for Plasma Fractionation providers across the Globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of go to Market Strategies and identifying the blue ocean for its offerings.
Ask For Discounts: https://univdatos.com/get-a-free-sample-form-php/?product_id=18131
1. By Product (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others)
2. By Application (Neurology, Immunology, Hematology, Critical care, Pulmonology, Others)
3. By End-User (Hospitals & Clinics, Clinical Research Laboratories, Others)
4. By Region (North America, Europe, Asia-Pacific, Rest of World)
5. By Company (Baxter International Inc., Bio product laboratory, Biotest AG, CSL Ltd., Grifols SA, Kedrion S.P.A (Kedrion Biopharma Inc.), LFB S. A., Octapharma AG, Sanquin Blood Supply Foundation, Takeda Pharmaceutical Company Limited, etc.)
Key questions answered in the study:
1. What are the current and future trends of the Plasma Fractionation industry?
2. How the industry has been evolving in terms of end-user demand and application areas?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Plasma Fractionation industry?
What is the customer orientation, purchase behavior, and expectations from the Plasma Fractionation firms across various regions?
Read More Information Here: https://univdatos.com/report/plasma-fractionation-market/
Table of Content:-
1. MARKET INTRODUCTION
2. RESEARCH METHODOLOGY OR ASSUMPTION
3. MARKET SYNOPSIS
4. EXECUTIVE SUMMARY
5 PLASMA FRACTIONATION MARKET COVID-19 IMPACT
6 PLASMA FRACTIONATION MARKET REVENUE (USD BN), 2019-2027F
7 MARKET INSIGHTS BY HARVESTING METHOD
8 MARKET INSIGHTS BY APPLICATION
9 MARKET INSIGHTS BY END-USER
10 MARKET INSIGHTS BY REGION
11 PLASMA FRACTIONATION MARKET DYNAMICS
12 PLASMA FRACTIONATION MARKET OPPORTUNITIES
13 PLASMA FRACTIONATION MARKET TRENDS
14 LEGAL AND REGULATORY FRAMEWORK
15 DEMAND AND SUPPLY SIDE ANALYSIS
16 VALUE CHAIN ANALYSIS
17 COMPETITIVE SCENARIO
18 COMPANY PROFILED
About UnivDatos Market Insights
UnivDatos Market Insights (UMI) is a passionate market research firm and a subsidiary of Universal Data Solutions. We believe in delivering insights through Market Intelligence Reports, Customized Business Research, and Primary Research. Our research studies are spread across topics across the world, we cover markets in over 100 countries using smart research techniques and agile methodologies. We offer in-depth studies, detailed analysis, and customized reports that help shape winning business strategies for our clients.
UnivDatos Market Insights